{"id":3111,"date":"2017-03-13T15:41:19","date_gmt":"2017-03-13T19:41:19","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-publie-ses-resultats-financiers-2016\/"},"modified":"2026-09-24T00:09:59","modified_gmt":"2026-09-24T04:09:59","slug":"gensight-biologics-publie-ses-resultats-financiers-2016","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2017\/03\/13\/gensight-biologics-publie-ses-resultats-financiers-2016\/","title":{"rendered":"GenSight Biologics publie ses r\u00e9sultats financiers 2016"},"content":{"rendered":"\nParis, 13 mars 2017 \u2013<\/strong> GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui ses r\u00e9sultats financiers pour l\u2019exercice 2016.\n\nInformation financi\u00e8re s\u00e9lectionn\u00e9e (IFRS)<\/strong>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
In million euros<\/td>\n2015<\/td>\n2016<\/td>\n<\/tr>\n
Operating income<\/td>\n3.6<\/td>\n3.0<\/td>\n<\/tr>\n
Research and development expenses<\/td>\n(10.7)<\/td>\n(18.5)<\/td>\n<\/tr>\n
General and administrative expenses<\/td>\n(6.5)<\/td>\n(6.5)<\/td>\n<\/tr>\n
Operating profit (loss)<\/td>\n(13.7)<\/td>\n(22.0)<\/td>\n<\/tr>\n
Net profit (loss)<\/td>\n(13.7)<\/td>\n(22.1)<\/td>\n<\/tr>\n
EPS (in \u20ac per share)<\/td>\n(1.21)<\/td>\n(1.36)<\/td>\n<\/tr>\n
Net cash flows from operating activities<\/td>\n(12.1)<\/td>\n(19.6)<\/td>\n<\/tr>\n
Net cash flows from financing activities<\/td>\n30.9<\/td>\n43.7<\/td>\n<\/tr>\n
Net cash flows<\/td>\n19.4<\/td>\n23.9<\/td>\n<\/tr>\n
Cash and cash equivalents at closing<\/td>\n30.1<\/td>\n54.0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nLes produits op\u00e9rationnels<\/strong> de la Soci\u00e9t\u00e9 ont diminu\u00e9 de 15,7% passant de 3,6 millions d\u2019euros en 2015 \u00e0 3,0 millions d\u2019euros en 2016. Ces produits ont \u00e9t\u00e9 principalement g\u00e9n\u00e9r\u00e9s par le Cr\u00e9dit Imp\u00f4t Recherche, qui s\u2019est \u00e9lev\u00e9 \u00e0 2,9 millions d\u2019euros pour chacune des deux p\u00e9riodes, et par une subvention re\u00e7ue en 2014 et reconnue prorata temporis sur trois ann\u00e9es.\n\nLes d\u00e9penses \u00a0de recherche \u00a0et d\u00e9veloppement<\/strong> ont augment\u00e9 de 72,8% passant de 10,7 millions d\u2019euros en 2015 \u00e0 18,5 millions d\u2019euros en 2016. Cette variation refl\u00e8te l\u2019acc\u00e9l\u00e9ration des activit\u00e9s de R&D d’une part, \u00e0 la fois sur les fronts de d\u00e9veloppement pr\u00e9clinique et clinique, et le renforcement des \u00e9quipes d\u00e9di\u00e9es \u00e0 la recherche et au d\u00e9veloppement pour conduire ces activit\u00e9s.\n\nLes frais g\u00e9n\u00e9raux<\/strong> restent stables sur la p\u00e9riode, repr\u00e9sentant 6,5 millions d\u2019euros en 2015 et 2016.\n\nLa perte nette<\/strong> de l\u2019exercice 2016 s\u2019\u00e9l\u00e8ve \u00e0 (22,1) millions d\u2019euros contre une perte de (13,7) millions d\u2019euros au titre de 2015. La perte par action \u00e9mise (nombre moyen pond\u00e9r\u00e9 d\u2019actions en circulation au cours de l\u2019exercice) s\u2019est \u00e9lev\u00e9e respectivement \u00e0 (1,36) et (1,21) euros par action pour les exercices 2016 et 2015.\n\nLes flux de tr\u00e9sorerie nets li\u00e9s aux activit\u00e9s op\u00e9rationnelles<\/strong> en 2016 et 2015 se sont \u00e9lev\u00e9s respectivement \u00e0 (19,6) millions d\u2019euros et (12,1) millions d\u2019euros, sous l\u2019effet principalement de l\u2019accroissement des activit\u00e9s de recherche et d\u00e9veloppement.\n\nLes flux de tr\u00e9sorerie nets li\u00e9s aux activit\u00e9s de financement<\/strong> se sont \u00e9lev\u00e9s \u00e0 43,7 millions d\u2019euros en 2016 contre 30,9 millions d\u2019euros un an plus t\u00f4t, refl\u00e9tant le produit net de l\u2019augmentation de capital r\u00e9alis\u00e9e dans le cadre de l\u2019introduction en bourse de la Soci\u00e9t\u00e9 sur le march\u00e9 Euronext Paris en juillet 2016.\n

\u00c0 propos \u00a0de GenSight Biologics<\/h2>\nGenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (Mitochondrial Targeting Sequence, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. Le candidat m\u00e9dicament le plus avanc\u00e9 de GenSight Biologics, GS010, est en Phase III pour le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), une maladie mitochondriale rare qui conduit \u00e0 une perte irr\u00e9versible de la vue chez les adolescents et les jeunes adultes. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intravitr\u00e9enne dans chaque \u0153il.\n","protected":false},"excerpt":{"rendered":"

Paris, 13 mars 2017 \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui ses r\u00e9sultats financiers pour l\u2019exercice 2016. Information financi\u00e8re s\u00e9lectionn\u00e9e (IFRS) In […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[],"news-type":[],"post-year":[],"class_list":["post-3111","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers"],"acf":[],"yoast_head":"\nGenSight Biologics publie ses r\u00e9sultats financiers 2016 - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2017\/03\/13\/gensight-biologics-publie-ses-resultats-financiers-2016\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics publie ses r\u00e9sultats financiers 2016 - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, 13 mars 2017 \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui ses r\u00e9sultats financiers pour l\u2019exercice 2016. Information financi\u00e8re s\u00e9lectionn\u00e9e (IFRS) In […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2017\/03\/13\/gensight-biologics-publie-ses-resultats-financiers-2016\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2017-03-13T19:41:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:09:59+00:00\" \/>\n<meta name=\"author\" content=\"editeur\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"editeur\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/03\\\/13\\\/gensight-biologics-publie-ses-resultats-financiers-2016\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/03\\\/13\\\/gensight-biologics-publie-ses-resultats-financiers-2016\\\/\"},\"author\":{\"name\":\"editeur\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\"},\"headline\":\"GenSight Biologics publie ses r\u00e9sultats financiers 2016\",\"datePublished\":\"2017-03-13T19:41:19+00:00\",\"dateModified\":\"2026-09-24T04:09:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/03\\\/13\\\/gensight-biologics-publie-ses-resultats-financiers-2016\\\/\"},\"wordCount\":610,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/03\\\/13\\\/gensight-biologics-publie-ses-resultats-financiers-2016\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/03\\\/13\\\/gensight-biologics-publie-ses-resultats-financiers-2016\\\/\",\"name\":\"GenSight Biologics publie ses r\u00e9sultats financiers 2016 - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2017-03-13T19:41:19+00:00\",\"dateModified\":\"2026-09-24T04:09:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/03\\\/13\\\/gensight-biologics-publie-ses-resultats-financiers-2016\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/03\\\/13\\\/gensight-biologics-publie-ses-resultats-financiers-2016\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2017\\\/03\\\/13\\\/gensight-biologics-publie-ses-resultats-financiers-2016\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics publie ses r\u00e9sultats financiers 2016\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\",\"name\":\"editeur\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"caption\":\"editeur\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics publie ses r\u00e9sultats financiers 2016 - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2017\/03\/13\/gensight-biologics-publie-ses-resultats-financiers-2016\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics publie ses r\u00e9sultats financiers 2016 - GenSight Biologics","og_description":"Paris, 13 mars 2017 \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui ses r\u00e9sultats financiers pour l\u2019exercice 2016. Information financi\u00e8re s\u00e9lectionn\u00e9e (IFRS) In […]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2017\/03\/13\/gensight-biologics-publie-ses-resultats-financiers-2016\/","og_site_name":"GenSight Biologics","article_published_time":"2017-03-13T19:41:19+00:00","article_modified_time":"2026-09-24T04:09:59+00:00","author":"editeur","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"editeur","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/03\/13\/gensight-biologics-publie-ses-resultats-financiers-2016\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/03\/13\/gensight-biologics-publie-ses-resultats-financiers-2016\/"},"author":{"name":"editeur","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a"},"headline":"GenSight Biologics publie ses r\u00e9sultats financiers 2016","datePublished":"2017-03-13T19:41:19+00:00","dateModified":"2026-09-24T04:09:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/03\/13\/gensight-biologics-publie-ses-resultats-financiers-2016\/"},"wordCount":610,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/03\/13\/gensight-biologics-publie-ses-resultats-financiers-2016\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2017\/03\/13\/gensight-biologics-publie-ses-resultats-financiers-2016\/","name":"GenSight Biologics publie ses r\u00e9sultats financiers 2016 - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2017-03-13T19:41:19+00:00","dateModified":"2026-09-24T04:09:59+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/03\/13\/gensight-biologics-publie-ses-resultats-financiers-2016\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2017\/03\/13\/gensight-biologics-publie-ses-resultats-financiers-2016\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2017\/03\/13\/gensight-biologics-publie-ses-resultats-financiers-2016\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics publie ses r\u00e9sultats financiers 2016"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a","name":"editeur","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","caption":"editeur"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3111"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3111\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3111"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3111"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3111"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3111"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}